Loading
Comparing the competing subtype schemes across trials and public data, this study found the two-type tumour-intrinsic scheme the most reproducible and built PurIST, a classifier that works on one biopsy at a time and relates to FOLFIRINOX response.
Three major subtype classification schemas were assessed against results from two clinical trials and by meta-analysis of public expression data for robustness and clinical relevance. A tumour-intrinsic two-subtype schema was most robust, replicable and clinically relevant. A single-sample classifier, PurIST, was developed by penalised logistic regression, with replicable performance across platforms and sample types including low-input biopsies; PurIST subtypes associated with prognosis and with treatment response to FOLFIRINOX.
PurIST is the assay form of the Moffitt subtypes and the tool prospective subtype-stratified trials use.
Shares Clinical Cancer Research, RNA sequencing & expression profiling, Pancreatic ductal adenocarcinoma.
Shares Clinical Cancer Research, FOLFIRINOX / mFOLFIRINOX, RNA sequencing & expression profiling, Pancreatic ductal adenocarcinoma.
Shares Clinical Cancer Research, FOLFIRINOX / mFOLFIRINOX, RNA sequencing & expression profiling, Pancreatic ductal adenocarcinoma.
Shares Clinical Cancer Research, Pancreatic ductal adenocarcinoma.
Shares FOLFIRINOX / mFOLFIRINOX, Pancreatic ductal adenocarcinoma.
Shares RNA sequencing & expression profiling, Pancreatic ductal adenocarcinoma.
Shares FOLFIRINOX / mFOLFIRINOX, Pancreatic ductal adenocarcinoma.
Shares FOLFIRINOX / mFOLFIRINOX, Pancreatic ductal adenocarcinoma.